MAPT and Alzheimer disease: The publication by Kandimalla et al. demonstrates that a partial reduction in Drp1 decreases the levels of phosphorylated tau in AD and also reduces mitochondrial dysfunction, having a neuroprotective effect and enhancing synaptic activity [56].